Healthcare [ 5/11 ] | Drug Manufacturers—General [ 69/112 ]
US | NYSE | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 27, 23 | 2.46 Decreased by -24.07% | 2.46 |
| Feb 9, 23 | 3.60 Increased by +8.76% | 3.56 Increased by +0.32% |
| Oct 28, 22 | 3.66 Increased by +9.91% | 3.57 Increased by +0.71% |
| Jul 29, 22 | 3.37 Increased by +9.06% | 3.31 Increased by +0.55% |
| Apr 29, 22 | 3.24 Increased by +9.83% | 3.14 Increased by +1.01% |
| Feb 2, 22 | 3.31 Increased by +13.36% | 3.29 Increased by +0.18% |
| Oct 29, 21 | 3.33 Increased by +17.67% | 3.22 Increased by +1.06% |
| Jul 30, 21 | 3.09 Increased by +32.05% | 3.09 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 12.22 B Decreased by -9.70% | 239.00 M Decreased by -94.68% | Increased by +1.96% Decreased by -94.11% |
| Dec 31, 22 | 15.12 B Increased by +1.58% | 2.47 B Decreased by -38.86% | Increased by +16.35% Decreased by -39.81% |
| Sep 30, 22 | 14.81 B Increased by +3.28% | 3.95 B Increased by +24.22% | Increased by +26.66% Increased by +20.28% |
| Jun 30, 22 | 14.58 B Increased by +4.47% | 924.00 M Increased by +20.63% | Increased by +6.34% Increased by +15.47% |
| Mar 31, 22 | 13.54 B Increased by +4.06% | 4.49 B Increased by +26.37% | Increased by +33.17% Increased by +21.44% |
| Dec 31, 21 | 14.89 B Increased by +7.42% | 4.04 B Increased by +11.14 K% | Increased by +27.17% Increased by +10.36 K% |
| Sep 30, 21 | 14.34 B Increased by +11.16% | 3.18 B Increased by +37.74% | Increased by +22.17% Increased by +23.91% |
| Jun 30, 21 | 13.96 B Increased by +33.90% | 766.00 M Increased by +203.79% | Increased by +5.49% Increased by +177.52% |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.